German Scientists Develop Nasal Covid-19 Vaccine Showing Early Promise
In a breakthrough that could potentially halt the spread of Covid-19, scientists in Germany have successfully developed a nasal vaccine that can shut down the virus's first foothold in the body. The vaccine, made with a live but weakened form of the coronavirus, has shown promising results in hamster studies by blocking the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The new approach to vaccination involves boosting mucosal immunity, beefing up immune defenses in the tissues that line the upper airways, where the virus would land and begin to infect our cells. This method is being explored as a potential solution to prevent the spread of infection. Researchers are trying to harness this type of immunity, which can provide long-lasting protection against infections.
The vaccine's development is built on an old idea - weakening a virus so it's no longer a threat and then giving it to people so their immune systems can learn to recognize and fight it off. The German team has successfully manipulated the genetic material in the virus to make it harder for cells to translate, effectively hobbling the virus without making the body sick.
In the hamster studies, two doses of the nasal vaccine created a stronger immune response than other types of vaccines used in clinical trials. The researchers believe that this approach could provide better protection against new variants of the virus.
However, experts caution that more tests need to be conducted before the vaccine can be widely used. "They did a very nice job," said Dr. Greg Poland, who designs vaccines at the Mayo Clinic. "Now it just needs to be repeated."
At least four nasal vaccines for Covid-19 have reached late-stage testing in people according to the World Health Organization's vaccine tracker. Other nasal vaccines are nearing completion of human studies, including one developed by a company called Codagenix.
While this development holds promise, researchers are also aware that respiratory infections can be tough targets for inhaled vaccines. FluMist, a live but weakened form of the flu virus, has shown limited effectiveness in adults due to existing immune memory.
The new nasal vaccine is being eagerly watched by scientists, with results from Codagenix's studies expected later this year. "They will be very important in order to know whether this kind of attempt is basically promising or not," said Emanuel Wyler, the study author.
Despite the challenges ahead, researchers remain optimistic that a pan-coronavirus vaccine could provide long-lasting protection against future variants.
In a breakthrough that could potentially halt the spread of Covid-19, scientists in Germany have successfully developed a nasal vaccine that can shut down the virus's first foothold in the body. The vaccine, made with a live but weakened form of the coronavirus, has shown promising results in hamster studies by blocking the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The new approach to vaccination involves boosting mucosal immunity, beefing up immune defenses in the tissues that line the upper airways, where the virus would land and begin to infect our cells. This method is being explored as a potential solution to prevent the spread of infection. Researchers are trying to harness this type of immunity, which can provide long-lasting protection against infections.
The vaccine's development is built on an old idea - weakening a virus so it's no longer a threat and then giving it to people so their immune systems can learn to recognize and fight it off. The German team has successfully manipulated the genetic material in the virus to make it harder for cells to translate, effectively hobbling the virus without making the body sick.
In the hamster studies, two doses of the nasal vaccine created a stronger immune response than other types of vaccines used in clinical trials. The researchers believe that this approach could provide better protection against new variants of the virus.
However, experts caution that more tests need to be conducted before the vaccine can be widely used. "They did a very nice job," said Dr. Greg Poland, who designs vaccines at the Mayo Clinic. "Now it just needs to be repeated."
At least four nasal vaccines for Covid-19 have reached late-stage testing in people according to the World Health Organization's vaccine tracker. Other nasal vaccines are nearing completion of human studies, including one developed by a company called Codagenix.
While this development holds promise, researchers are also aware that respiratory infections can be tough targets for inhaled vaccines. FluMist, a live but weakened form of the flu virus, has shown limited effectiveness in adults due to existing immune memory.
The new nasal vaccine is being eagerly watched by scientists, with results from Codagenix's studies expected later this year. "They will be very important in order to know whether this kind of attempt is basically promising or not," said Emanuel Wyler, the study author.
Despite the challenges ahead, researchers remain optimistic that a pan-coronavirus vaccine could provide long-lasting protection against future variants.